Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who have maintained a molecular response can successfully discontinue treatment without relapsing. Treatment free remission (TFR) can be reached b...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuckey, Ruth, López-Rodríguez, Juan Francisco, Sánchez-Sosa, Santiago, Segura-Díaz, Adrián, Sánchez-Farías, Nuria, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769711/
https://www.ncbi.nlm.nih.gov/pubmed/33437662
http://dx.doi.org/10.5306/wjco.v11.i12.996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769711/
https://www.ncbi.nlm.nih.gov/pubmed/33437662
http://dx.doi.org/10.5306/wjco.v11.i12.996

Ejemplares similares